Shared mechanisms for metastasis and drug resistance in prostate cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Prostate cancer (PCa) metastasis and drug resistance are interconnected, influencing treatment outcomes. Future therapies should target shared mechanisms for dual inhibition, improving patient survival.
Area Of Science
- Oncology
- Cancer Biology
- Translational Medicine
Background
- Prostate cancer (PCa) is a leading malignancy in men, with metastasis and drug resistance severely affecting prognosis.
- Metastasis and drug resistance were historically studied separately but are now recognized as closely interrelated processes in cancer progression.
- Understanding their interplay is crucial for developing effective treatments for advanced PCa.
Purpose Of The Study
- To review in vivo and in vitro models for studying PCa metastasis and drug resistance.
- To investigate shared mechanisms underlying PCa metastasis and drug resistance.
- To summarize current and investigational therapies for PCa, highlighting the need for integrated treatment strategies.
Main Methods
- Comprehensive literature review of studies on PCa metastasis and drug resistance.
- Analysis of common signaling pathways, including the androgen receptor signaling pathway.
- Examination of the tumor microenvironment's role in PCa progression.
- Summary of therapeutic agents and drugs in clinical trials for PCa.
Main Results
- Metastasis can facilitate drug resistance, and drug resistance can promote further metastasis through shared pathways.
- The androgen receptor signaling pathway, tumor microenvironment, and cellular signaling pathways are key regulators of both processes.
- Current research and therapies often address metastasis or drug resistance independently, not concurrently.
- Existing models have limitations in fully recapitulating the complexity of PCa metastasis and drug resistance.
Conclusions
- There is a critical need to develop therapeutic strategies that simultaneously target both prostate cancer metastasis and drug resistance.
- Future drug development should focus on integrated regulation of shared molecular mechanisms to overcome treatment challenges.
- A dual inhibition approach holds promise for improving clinical outcomes in patients with advanced prostate cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...